Skip to content
Screener

Savara SVRA Financing Cash Flow

Financing Cash Flow at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
-$29.41M-2,458%
XER
Xeris Biopharma Holdings, Inc.XERS
-$8.84M-182%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$52.8M-3,386%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$2.53M+314%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$4.65M-166%
PVL
Palvella TherapeuticsPVLA
$214.73M+17,964%

Other financials

Income statement

See full
Revenue-
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%
EPS (diluted)-$0.16-14.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.17B+152%
Enterprise value$1.16B+143%

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Savara’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219371
Line itemFor the three months ended March 31, 2026For the three months ended March 31, 2025
Proceeds from long-term debt, net29,598
Proceeds from exercise of stock options45165
Repurchase of shares for minimum tax withholdings(240)(215)
Net cash provided (used in) by financing activities(195)2,318
Effect of exchange rate changes on cash and cash equivalents74(30)
Increase in cash and cash equivalents5,6114,428
Cash and cash equivalents beginning of period33,18015,128
Cash and cash equivalents end of period$38,791$19,556

Cover / Front Matter

FAQ

What is Savara's financing cash flow?
Savara (SVRA) reported financing cash flow of -$195K in Q1 2026.
How has Savara's financing cash flow changed year-over-year?
Savara's financing cash flow decreased by 108.4% year-over-year, from $2.32M to -$195K.
What is the long-term trend for Savara's financing cash flow?
Over 3 years (2021 to 2024), Savara's financing cash flow has grown at a -0.7% compound annual growth rate (CAGR), from $120.81M to $118.42M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Savara's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude